Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

anti-CCR8 monoclonal antibody GS-1811

A humanized immunoglobulin G1 (IgG1) afucosylated monoclonal antibody against C-C-chemokine receptor 8 (CCR8), with potential immunomodulating and antineoplastic activities. Upon administration, anti-CCR8 monoclonal antibody GS-1811 targets and binds to CCR8 on CCR8-positive, immunosuppressive tumor-infiltrating T-regulatory (TITR) cells in the tumor microenvironment (TME), and prevents chemokine ligand 1 (CCL1)-CCR8-mediated signaling. GS-1811 depletes CCR8-positive TITR cells via antibody-dependent cell-mediated cytotoxicity (ADCC), which may reactivate antitumor immune responses. CCR8 is specifically expressed by TITR cells in multiple types of cancer and plays a key role in immunosuppression.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-C-C-chemokine receptor 8 monoclonal antibody GS-1811
Code name:GS 1811
GS-1811
GS1811
JTX 1811
JTX-1811
JTX1811
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search